US EditionTalphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
- On May 14, 2025, in San Mateo, California, Talphera, a specialty pharmaceutical company, released its financial performance for the first quarter of 2025 along with a corporate update.
- This announcement followed Talphera's March 2025 FDA approval of a Prior Approval Supplement reducing the NEPHRO CRRT study patient count from 166 to 70 and broadening enrollment criteria.
- The NEPHRO CRRT study is a prospective, double-blinded trial conducted at up to 14 intensive care units across the U.S., enrolling 70 adult patients receiving renal replacement therapy who are unable to use heparin or have an increased risk of bleeding.
- As of March 31, 2025, Talphera reported $9.8 million in cash and investments, a figure that includes $4.4 million received from the initial segment of a $14.8 million financing deal finalized on April 2, 2025.
- Talphera plans to activate five additional high-enrollment clinical sites by mid-2025, aims to complete the study by the end of the year, and estimates its cash-based operational costs for 2025 will range from $17 million to $19 million.
33 Articles
33 Articles
The Daily News
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Anticipates initiating the Company's Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) agreement with U.S. Food and…
Montana Standard
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million
Missoulian
chicagostarmedia.comArmata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
LOS ANGELES, May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today…
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has reported its Q1 2025 financial results, showing mixed performance. The company's net product revenues increased 55% year-over-year to $163.6 thousand, primarily driven by domestic sales of ARAKODA®. Gross profit saw significant growth of 124%, reaching $90.3 thousand compared to $40.2 thousand in Q1 2024.However, operating expenses rose to $2.09 million from $1.41 million in the previous year, with $…
Coverage Details
Bias Distribution
- 80% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
